JP2023533721A - トリヌクレオチドキャップ類似体、それらの調製、及び使用 - Google Patents

トリヌクレオチドキャップ類似体、それらの調製、及び使用 Download PDF

Info

Publication number
JP2023533721A
JP2023533721A JP2023500053A JP2023500053A JP2023533721A JP 2023533721 A JP2023533721 A JP 2023533721A JP 2023500053 A JP2023500053 A JP 2023500053A JP 2023500053 A JP2023500053 A JP 2023500053A JP 2023533721 A JP2023533721 A JP 2023533721A
Authority
JP
Japan
Prior art keywords
bis
aminopropyl
rna
dye
glycero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500053A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022006368A5 (https=
JP2023533721A5 (https=
Inventor
アニルクマール コラ
センシルヴェラン アナマライ
シャンムガスンダラム ムシアン
ロバート ポッター
タイソン ヴォンダーフェヒト
Original Assignee
ライフ テクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ テクノロジーズ コーポレーション filed Critical ライフ テクノロジーズ コーポレーション
Publication of JP2023533721A publication Critical patent/JP2023533721A/ja
Publication of JPWO2022006368A5 publication Critical patent/JPWO2022006368A5/ja
Publication of JP2023533721A5 publication Critical patent/JP2023533721A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1247DNA-directed RNA polymerase (2.7.7.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07006DNA-directed RNA polymerase (2.7.7.6)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023500053A 2020-07-02 2021-07-01 トリヌクレオチドキャップ類似体、それらの調製、及び使用 Pending JP2023533721A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047465P 2020-07-02 2020-07-02
US63/047,465 2020-07-02
US202163197607P 2021-06-07 2021-06-07
US63/197,607 2021-06-07
PCT/US2021/040037 WO2022006368A2 (en) 2020-07-02 2021-07-01 Trinucleotide cap analogs, preparation and uses thereof

Publications (3)

Publication Number Publication Date
JP2023533721A true JP2023533721A (ja) 2023-08-04
JPWO2022006368A5 JPWO2022006368A5 (https=) 2025-01-30
JP2023533721A5 JP2023533721A5 (https=) 2025-01-30

Family

ID=77051197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500053A Pending JP2023533721A (ja) 2020-07-02 2021-07-01 トリヌクレオチドキャップ類似体、それらの調製、及び使用

Country Status (6)

Country Link
US (2) US12385039B2 (https=)
EP (1) EP4175967A2 (https=)
JP (1) JP2023533721A (https=)
KR (1) KR20230034333A (https=)
CN (1) CN115803333A (https=)
WO (1) WO2022006368A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025107988A (ja) * 2024-01-09 2025-07-22 ハンチョウ ティアンロン ファーマシューティカル カンパニー、リミテッド C6’置換ロック核酸修飾キャップ類似体及びその使用
JP2025168238A (ja) * 2024-04-26 2025-11-07 ベイジン ユーケアケチュアン ファーマシューティカル テクノロジー カンパニー リミテッド リボース修飾キャップ付き類似体及びその使用
WO2026014365A1 (ja) * 2024-07-08 2026-01-15 国立大学法人東海国立大学機構 5´キャップアナログ

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022266032A1 (en) * 2021-06-14 2022-12-22 Generation Bio Co. Cationic lipids and compositions thereof
CN118978560A (zh) * 2021-08-27 2024-11-19 上海兆维科技发展有限公司 一种加帽类似物及其应用
CN115260264B (zh) 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
WO2023230533A1 (en) * 2022-05-25 2023-11-30 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
CN117430652A (zh) * 2022-07-22 2024-01-23 广州市恒诺康医药科技有限公司 用于rna加帽的环状取代化合物及其应用
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA
CN118373866A (zh) * 2023-01-20 2024-07-23 深圳瑞吉生物科技有限公司 一种用于核酸的5’端加帽的化合物及其应用
CN121263517A (zh) * 2023-02-01 2026-01-02 美国金斯瑞公司 体外转录方法和用于其中的化合物
CN116478226B (zh) * 2023-03-07 2025-08-19 江苏申基生物科技有限公司 一种锁核苷帽类似物和应用
US20250230184A1 (en) * 2023-12-29 2025-07-17 Industrial Technology Research Institute Compound, pharmaceutical composition, kit for capped rna transcript, and method for in vitro
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
CN117510564B (zh) * 2024-01-08 2024-03-08 苏州诺维康生物科技有限公司 一种医药中间体N2-Ac-5'-O-DMT-2'-O-炔丙基鸟苷的合成方法
WO2025264140A1 (ru) * 2024-06-18 2025-12-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тринуклеотидный кэпирующий реагент, способ его получения и применение
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059475A1 (en) * 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
JP2018527015A (ja) * 2015-09-21 2018-09-20 トリリンク バイオテクノロジーズ インコーポレイテッド 5’キャップ付rnaを合成するための組成物および方法
WO2019175356A1 (en) * 2018-03-15 2019-09-19 Biontech Rna Pharmaceuticals Gmbh 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603209A (en) 1984-09-07 1986-07-29 The Regents Of The University Of California Fluorescent indicator dyes for calcium ions
US4714763A (en) 1985-07-11 1987-12-22 Viomedics Inc. Novel oxazine-ureas and thiazine urea chromophors as fluorescent labels
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4849362A (en) 1988-05-19 1989-07-18 Smithkline Beckman Corporation Fluorescent intracellular calcium indicators
US4981977A (en) 1989-06-09 1991-01-01 Carnegie-Mellon University Intermediate for and fluorescent cyanine dyes containing carboxylic acid groups
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5501980A (en) 1994-05-20 1996-03-26 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5451343A (en) 1991-05-20 1995-09-19 Spectra Group Limited, Inc. Fluorone and pyronin y derivatives
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5242805A (en) 1991-08-23 1993-09-07 Molecular Probes, Inc. Long wavelength lipophilic fluorogenic glycosidase substrates
US5808044A (en) 1993-01-22 1998-09-15 Pharmacia Biotech Inc. Indocarbocyanine and benzindocarbocyanine phosphoramidites
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
US6008373A (en) 1995-06-07 1999-12-28 Carnegie Mellon University Fluorescent labeling complexes with large stokes shift formed by coupling together cyanine and other fluorochromes capable of resonance energy transfer
US5798276A (en) 1995-06-07 1998-08-25 Molecular Probes, Inc. Reactive derivatives of sulforhodamine 101 with enhanced hydrolytic stability
US6004536A (en) 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
JP2000508709A (ja) 1996-04-19 2000-07-11 アマーシャム・ファルマシア・バイオテック・ユーケイ・リミテッド スクアラート染料類および蛍光配列決定法におけるそれらの使用
US5846737A (en) 1996-07-26 1998-12-08 Molecular Probes, Inc. Conjugates of sulforhodamine fluorophores with enhanced fluorescence
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5877310A (en) 1997-04-25 1999-03-02 Carnegie Mellon University Glycoconjugated fluorescent labeling reagents
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6133445A (en) 1997-12-17 2000-10-17 Carnegie Mellon University Rigidized trimethine cyanine dyes
EP1078023B1 (en) 1998-04-08 2011-01-05 Corporation Luminex Luminescent compounds
US6002003A (en) 1998-04-14 1999-12-14 Beckman Instruments, Inc. Cyanine dye activating group with improved coupling selectivity
JP3983404B2 (ja) 1999-01-13 2007-09-26 本田技研工業株式会社 レーダ搭載車両用ゲート
US6664047B1 (en) 1999-04-30 2003-12-16 Molecular Probes, Inc. Aza-benzazolium containing cyanine dyes
EP1065250B1 (en) 1999-07-02 2004-12-08 Visen Medical, Inc. New fluorescent cyanine labels containing a sulfamido linker arm
WO2001021624A1 (en) 1999-09-20 2001-03-29 Fuji Photo Film Co., Ltd. Compounds for fluorescence labeling
AU2001279185B2 (en) 2000-08-04 2005-07-07 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
EP1322710B2 (en) 2000-09-29 2015-02-18 Life Technologies Corporation Modified carbocyanine dyes and their conjugates
US7446202B2 (en) 2003-12-05 2008-11-04 Molecular Probes, Inc. Cyanine dye compounds
US7776529B2 (en) 2003-12-05 2010-08-17 Life Technologies Corporation Methine-substituted cyanine dye compounds
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
CN101258220A (zh) 2004-09-16 2008-09-03 阿普里拉股份有限公司 荧光染料化合物,共轭物及其应用
JP5306811B2 (ja) 2005-05-11 2013-10-02 ライフ テクノロジーズ コーポレーション 2本鎖dnaへの高い選択性を有する蛍光化学物質及びそれらの使用
CN101454315B (zh) 2006-03-31 2016-08-17 应用生物系统有限责任公司 用于合成罗丹明-标记的寡核苷酸的试剂
US10053447B2 (en) 2010-12-21 2018-08-21 Pierce Biotechnology, Inc Fluorescent compounds
CN107326073A (zh) 2010-12-29 2017-11-07 生命技术公司 作为荧光参考标准品的 ddao 化合物
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
US9751868B2 (en) 2012-02-28 2017-09-05 Pierce Biotechnology, Inc. Benzocyanine compounds
CN104395306B (zh) 2012-03-02 2019-04-23 皮尔斯生物科技有限公司 作为生物分子的标记染料的吲哚衍生物
US20140255312A1 (en) 2013-03-07 2014-09-11 Greg Hermanson Cyanine compounds
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
AU2016342049B2 (en) 2015-10-22 2023-05-18 Modernatx, Inc. Herpes simplex virus vaccine
WO2017070620A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
MX2018004917A (es) 2015-10-22 2019-04-01 Modernatx Inc Vacuna de virus sincitial respiratorio.
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
BR112019008481A2 (pt) 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
US20200263231A1 (en) 2016-11-07 2020-08-20 Life Technologies Corporation Fluorogenic dyes for high sensitivity DNA detection
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
EP3551230A1 (en) 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3576751A4 (en) 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
PL248416B1 (pl) * 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059475A1 (en) * 2011-10-18 2013-04-25 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
JP2018527015A (ja) * 2015-09-21 2018-09-20 トリリンク バイオテクノロジーズ インコーポレイテッド 5’キャップ付rnaを合成するための組成物および方法
WO2019175356A1 (en) * 2018-03-15 2019-09-19 Biontech Rna Pharmaceuticals Gmbh 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANGEW CHEM INT ED., vol. 56, JPN6025034264, 2017, pages 15628 - 15632, ISSN: 0005811672 *
BIOORG MED CHEM., vol. 24, JPN6025034263, 2016, pages 1204 - 1208, ISSN: 0005811671 *
CHEM COMMUN., vol. 50, JPN6025034265, 2014, pages 4478 - 4481, ISSN: 0005811673 *
J AM CHEM SOC., vol. 131, JPN6025034262, 2009, pages 6365 - 1, ISSN: 0005668631 *
NUCLEIC ACIDS RESEARCH, vol. 48(4), JPN7025003718, 2020, pages 1607 - 1626, ISSN: 0005811670 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025107988A (ja) * 2024-01-09 2025-07-22 ハンチョウ ティアンロン ファーマシューティカル カンパニー、リミテッド C6’置換ロック核酸修飾キャップ類似体及びその使用
JP7788017B2 (ja) 2024-01-09 2025-12-17 ハンチョウ ティアンロン ファーマシューティカル カンパニー、リミテッド C6’置換ロック核酸修飾キャップ類似体及びその使用
JP2025168238A (ja) * 2024-04-26 2025-11-07 ベイジン ユーケアケチュアン ファーマシューティカル テクノロジー カンパニー リミテッド リボース修飾キャップ付き類似体及びその使用
JP7805500B2 (ja) 2024-04-26 2026-01-23 ベイジン ユーケアケチュアン ファーマシューティカル テクノロジー カンパニー リミテッド リボース修飾キャップ付き類似体及びその使用
WO2026014365A1 (ja) * 2024-07-08 2026-01-15 国立大学法人東海国立大学機構 5´キャップアナログ

Also Published As

Publication number Publication date
CN115803333A (zh) 2023-03-14
US20220002716A1 (en) 2022-01-06
US12385039B2 (en) 2025-08-12
WO2022006368A3 (en) 2022-03-17
KR20230034333A (ko) 2023-03-09
WO2022006368A2 (en) 2022-01-06
EP4175967A2 (en) 2023-05-10
US20250333729A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
JP2023533721A (ja) トリヌクレオチドキャップ類似体、それらの調製、及び使用
US20210292761A1 (en) Compositions comprising circular polyribonucleotides and uses thereof
AU2022249357A1 (en) Methods for identification and ratio determination of rna species in multivalent rna compositions
JP2025061102A (ja) 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
JP2024510421A (ja) Vlpエンテロウイルスワクチン
JP2022160454A (ja) 安定化尾部領域を含むポリヌクレオチド
US20230104113A1 (en) Delivery of compositions comprising circular polyribonucleotides
CN113271926A (zh) 脂质纳米颗粒的制备及其施用方法
JP2026040556A (ja) 環状ポリリボヌクレオチドを投与する方法
KR20190090848A (ko) 변형된 가이드 rna
CN121718542A (zh) 多尾和多帽mRNA及其用途
CA3218780A1 (en) Methods and compositions for genomic integration
JP2024511437A (ja) ポリヌクレオチド組成物、関連製剤、およびその使用方法
WO2024206835A1 (en) Circular mrna and production thereof
CN116940324A (zh) 脂质纳米颗粒球形核酸
WO2023165530A1 (zh) 提高rna分子的胞内翻译效率和/或稳定性的方法
EP4323517A2 (en) Compositions containing nucleic acid nanoparticles and processes related to alteration of their physicochemical characteristics
EP4722375A1 (en) Efficient in vitro transcription of artificial mrna with highly modified 5' ends
WO2026078020A2 (en) Efficient in vitro transcription of artificial mrna with highly modified 5' ends
Aditham Site-specific chemical and topological modifications to augment mRNA therapeutic potential
WO2025054383A1 (en) Chemical stability of mrna
CN114929288A (zh) 合成的修饰的rna及其用途
HK40079977A (en) Synthetic modified rna and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260309